A paper published Thursday in Clinical Infectious Diseases examines how barriers to appropriate diagnostic tools led to missed opportunities to curb antibiotic resistance and recommends steps to develop and expand the use of tests that can identify resistant bacteria.
Barbara D. Alexander, M.D., MHS, FIDSA – President, Infectious Diseases Society of America on today’s Pfizer/BioNTech application for Emergency Use Authorization of its COVID-19 vaccine candidate
With numbers of infections, illnesses, hospitalizations and deaths caused by COVID-19 at record highs as this holiday season begins, the risks posed by the spread of the coronavirus are more dangerous than at any time since its emergence last December.
Cornelius J. Clancy, M.D., member of the Infectious Diseases Society of America’s Antimicrobial Resistance Committee, presented on behalf of IDSA at today’s Food and Drug Administration public meeting to provide feedback on an FDA concept paper regarding the ranking of antimicrobial drugs according to their importance
IDSA awarded seven institutions the designation of Antimicrobial Stewardship Center of Excellence. The designated hospitals have created stewardship programs led by infectious diseases-trained physicians and pharmacists that advance science in antimicrobial resistance.
Anthony Fauci, M.D., FIDSA, director of the National Institute of Allergy and Infectious Diseases, kicked off this year’s premier virtual infectious diseases conference with an overview of the public health and scientific challenges of COVID-19 in the United States. Login to this year’s program now.